Dr. Reddy's, Ceragenix to market EpiCeram for atopic dermatitis

DENVER Dr. Reddy’s Laboratories has inked an exclusive distribution and supply agreement with the biotech company Ceragenix Pharmaceuticals to commercialize EpiCeram, a topical cream used for treating atopic dermatitis and other dry skin conditions.

The agreement gives Dr. Reddy’s exclusivity in the U.S. for the distribution and marketing of the drug, while Ceragenix will be responsible for the manufacturing and supply of the product. Ceragenix will receive certain milestone payments over the agreement period. Upon commercialization of the product, Ceragenix will receive royalty payments based on net sales.

Steven Porter, chairman and chief executive officer of Ceragenix said, “We are very pleased to be partnering with Dr. Reddy’s to commercialize EpiCeram. We are very impressed with the team assembled by Dr. Reddy’s and we look to forward bringing this product into the market together. As we’ve stated in the past, we believe that patients and physicians alike will find EpiCeram’s combination of efficacy and safety profile to be a welcome alternative in the treatment of atopic dermatitis.”

Dr. Reddy’s expects to launch EpiCeram within a year through a new salesforce targeting dermatologists.